medigraphic.com
ISSN 0188-9796 (Print)

2003, Number 1

<< Back Next >>

Rev Endocrinol Nutr 2003; 11 (1)

What is the insulin level in a mexican people with normal body mass index?

Vázquez CC, Salinas OS, Gómez DRA, Rosso JMM, Jiménez VM, Argüero SR

Language: Spanish
References: 37
Page: 22-27
PDF size: 79.83 Kb.


ABSTRACT

High insulin serum levels are related with hypertension and coronary heart disease; the objective of the present work was to know the fasting insulin serum levels in subjects with body mass index (BMI) < 24 and normal glucose tolerance test. The glucose/insulin ratio was used as a marker for sensitivity or tisular resistance to this hormone. Sixty one healthy men and women, aged 20-65 year old were included, their weight, height, BMI and waist/hip ratio (WHR) was recorded and their levels of glucose and insulin measured in the fasting state and post an oral glucose tolerance test (OGTT). Total cholesterol (TC), tryglicerides (TG), fibrinogen, uric acid and cholesterol of high (HDL-C) and low (LDL-C) density lipoprotein were also determinated at fasting state. Statistical analysis were made with a SAS package using Student t test for differences between studied groups. Results: Weight, height, BMI, WHR, TC and TG were significatively higher in men, which also had a lower level of HDL-C. The insulin and glucose levels did not show significative differences between sexes, and for this reason where analyzed as only one group for statistical analysis. Subjects showing insulin resistance (GIR < 6) reached statistical significance with high levels of insulin at 0’= 22.7 ± 7.2 and after 75 g of oral glucose at 60’= 85.2 ± 41.5 and 120’= 71.2 ± 30.3 µU/mL and lower levels of HDL-C; 45.7 ± 10.1 mg/dL. The fasting insulin serum levels in a Mexican population with BMI < 24 and normal sensitivity to insulin (GIR > 6) were of 8.7 ± 3.2 µU/mL, 60 and 120 min levels were of 58.37 ± 44.08 and 50.87 ± 26.10 mU/mL respectively. We conclude that fasting insulin serum levels of 8.7 ± 3.2 µU/mL are representative levels when the subjects are without overweight, normal glucose metabolism and normal blood lipids, and is a practical method for assesing insulin resistance in common medical care.


REFERENCES

  1. Ferraninni E, Buzzigoli G, Bonadonna R, Giorico MA, Olegginim, Graziadei L. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-7.

  2. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-I) in hypertension are related to metabolic risk factors for cardiovascular disease. J Int Med 1990; 227: 273-8.

  3. Modan M, Halkin H, Almog S et al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75: 809-817.

  4. Baron AD, Lakk So M, Brechtel G, Edelman SU. Mechanism of insulin resistance in insulin-dependent diabetes mellitus: a major role for reduced skeletal muscle blood flow. J Clin Endocrinol Metab 1991; 73: 637-643.

  5. Fontbonne A, Charles MA, Thibutt N et al. Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: The Paris Prospective Study, 15 year follow-up. Diabetologia 1991; 34: 356-361.

  6. Zavaroni I, Bonora E, Pagliara M et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989; 320; 11:702-706.

  7. Zamora GJ, Yamoto KL, Lerman GI, Cardoso SG, Fajardo GA, Posadas RC. Clustering of metabolic disorders and hyperinsulinemia in Mexico City. Inter J Obesity 1996; 20: 311-318.

  8. Walton C, Godsland IF, Prondler AJ et al. Effect of body mass index and fat distribution on insulin sensitivity, secretion and clearance in non-obese healthy men. J Clin Endocrinol Metab 1992; 75: 170-175.

  9. Ducimetiere P, Richard J, Combien F. The pattern of subcutaneous fat distribution in middle aged men and the risk of coronary heart disease. The Paris Prospective Study. Int J Obes 1986; 10: 229-240.

  10. Donahue RP, Abbott RD, Bloom E et al. Central obesity and coronary heart disease. Lancet 1987; 1: 821-824.

  11. Morán C, Hernández E, Ruiz JE, Fonseca ME, Zárate A. La distribución del tejido adiposo tiene relación con los niveles de insulina en la mujer obesa. Ginec Obst Mex 1992; 60: 75-78.

  12. Hwang IS, Ho H, Hoffman BB, Reaven GM. Fructose induced insulin resistance and hypertension in rats. Hypertension 1987; 10: 512.

  13. Wright DW, Hansen RI, Mondon CE, Reaven GM. Sucrose induced insulin resistance in the rat: Modulation by exercise and diet. Am J Clin Nutr 1983; 38: 879.

  14. Reaven GM. Role of insulin resistance in human disease. Banting Lecture Diabetes 1988; 37: 1595-1607.

  15. Singer P, Godicke W, Voight S et al. Post prandial hyperinsulinemia in mild hypertension. Hypertension 1985; 7: 182-186.

  16. Shen DC, Shieh SM, Fuh MMT, Wu YD, Chen DI, Reaven GM. Resistance to insulin stimulated glucose uptake in patients with hypertension. J Clin Endocrinol Metab 1988; 66: 580-583.

  17. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990; 39: 167-74.

  18. Ferraninni E, Haffner SM, Stern M. Essential hypertension: An insulin-resistant state. J Cardiovasc Pharmacol 1990; 15(Suppl-5): 518-525.

  19. Saad MF, Lillioja S, Myomba B et al. Racial differences in the relation between blood pressure and insulin-resistance. N Engl J Med 1991; 324: 733-9.

  20. Müller DC, Elahi D, Pratley RE, Jobin JD, Andres R. An epidemiological test of the hyperinsulinemia-hypertension hypothesis. J Clin Endocrinol Metab 1993; 76: 544-548.

  21. Clansen T. Regulation of active Na/K transport in skeletal muscle. Physiol Rev 1986; 66: 542.

  22. Canessa M, Brugnara C, Escobales N. The Li-Na exchange and Na-K-Cl co transport systems in essential hypertension. Hypertension 1987; 10(Suppl-1): 4.

  23. Stout RW. Insulin and atheroma: 20 year perspective. Diabetes Care 1990; 13: 631.

  24. Vague P, Juhan-Vague I, Ailland MF et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor levels, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986; 35: 250-253.

  25. Hamsten A, Walldius G, Szamos A, Blomback, Eaire U et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardical infarction. Lancet 1987; 1: 3.

  26. Juhan-Vague J, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457.

  27. Nilsson TK, Sundell IB, Hellsten G, Hallman S. Reduced plasminogen activator inhibitor activity in high consumers of fruit, vegetable and root vegetable. J Intern Med 1990; 227: 267.

  28. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-63.

  29. Vázquez ChC, Brito ZO, Argüero SR, Lozano de los Santos H. Resistencia a la insulina: factor etiológico de la hipertensión arterial esencial y de la cardiopatía coronaria. Gac Med Mex 1993; 129: 339.

  30. Caro JF. Clinical Review 26: Insulin resistance in obese and non-obese man. J Clin Endocrinol Metab 1991; 73:4: 691-695.

  31. Programa SAS. Institute. Incorporation 1980, version 3.0.

  32. La Rosa JC. Dyslipoproteinemia in woman and the ederly. Med Clin North Am 1994; 78(1): 163-180.

  33. Jean-Pierre Després, Benoit Lamarche, Pascale Mauriégie, Bernard Cantin, Guilles Dagenais, Sital Moorjani, Paul J. Lupien. Hyperinsulinaemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.

  34. Ginsberg HN. Insulin resistance and cardiovacular disease. J Clin Invest 2000; 106: 453-458.

  35. American Diabetes Association. Consensus Development Conference on Insulin Resistance. Diabetes Care 1998; 21: 310-314.

  36. Alpízar SM, Escalante PJM. Modelo Mínimo, su aplicación para evaluar la sensibilidad a la insulina y la función de la célula beta del páncreas in vivo. Revista de Endocrinología y Nutrición 1998; 6: 1-6.

  37. Steven M, Hafner, González C, Miettinen H, Kennedy E, Stern MP. A prospective analysis of the HOMA model. Diabetes Care 1996; 19: 1138-1141.




2020     |     www.medigraphic.com